Prostate tumours from an Asian population:: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker

被引:13
作者
Chia, SJ
Tang, WY
Elnatan, J
Yap, WM
Goh, HS
Smith, DR
机构
[1] Tan Tock Seng Hosp, Mol Biol Lab, Singapore 308433, Singapore
[2] Tan Tock Seng Hosp, Dept Pathol, Singapore 308433, Singapore
[3] Tan Tock Seng Hosp, Dept Gen Surg, Singapore 308433, Singapore
关键词
immunohistochemistry; mutation; bax; bcl-2; p53; survival;
D O I
10.1054/bjoc.2000.1355
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Molecular studies have suggested that ethnicity may play a significant role in prostate tumorigenesis, but no information exists for groups other than Caucasian or Japanese patients. We examined 62 archival samples of prostate tumours from Asians of non-Japanese origin for the over-expression of p53, for the possible presence of mutated ras genes, for the overexpression of the bcl-2 and bax proteins, as well as directly for the presence of apoptotic cells by the TUNEL methodology. Gene lesions of both ras (0%) and p53 (3%) were rare. While bcl-2 expression was not observed in any sample, bax expression was noted in 76% of samples and was associated with a significantly worse patient prognosis both overall (P < 0.005) and specifically in Chinese patients (P < 0.02). Apoptotic cells were found in 61% of samples, and were significantly associated with the presence of bax expression (P = 0.002), but not patient survival. These results suggest that prostate rumours from non-Japanese Asians are genetically distinct from prostate tumour found in both Japanese and Caucasian patients, and that treatment modalities may need to be tailored for specific population groups. (C) 2000 Cancer Research Campaign.
引用
收藏
页码:761 / 768
页数:8
相关论文
共 45 条
[1]  
[Anonymous], 4 SING CANC REG
[2]  
[Anonymous], UROLOGIC PATHOLOGY
[3]  
ANWAR K, 1992, CANCER RES, V52, P5991
[4]  
Bauer JJ, 1995, CLIN CANCER RES, V1, P1295
[5]   Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer [J].
Bauer, JJ ;
Sesterhenn, IA ;
Mostofi, FK ;
McLeod, DG ;
Srivastava, S ;
Moul, JW .
JOURNAL OF UROLOGY, 1996, 156 (04) :1511-1516
[6]   The apoptotic and transcriptional transactivation activities of p53 can be dissociated [J].
Bissonnette, N ;
Wasylyk, A ;
Hunting, DJ .
BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1997, 75 (04) :351-358
[7]   Gene therapy for prostate cancer [J].
Bower, M ;
Waxman, J .
SEMINARS IN CANCER BIOLOGY, 1997, 8 (01) :3-9
[8]  
DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187
[9]  
Eastham JA, 1995, CLIN CANCER RES, V1, P1111
[10]   ALTERATIONS OF THE P53 GENE ARE ASSOCIATED WITH THE PROGRESSION OF A HUMAN PROSTATE CARCINOMA [J].
EFFERT, PJ ;
NEUBAUER, A ;
WALTHER, PJ ;
LIU, ET .
JOURNAL OF UROLOGY, 1992, 147 (03) :789-793